News for AXSM Stock

Axsome Therapeutics Provides Update on the New Drug Application (NDA) for AXS-14 for the Management of Fibromyalgia Axsome Therapeutics to Participate in Upcoming Investor Conferences Axsome Therapeutics Presents Data from Three of Its Innovative Neuroscience Programs at the American Society of Clinical Psychopharmacology (ASCP) 2025 Annual Meeting Axsome Therapeutics Settles SUNOSI® (solriamfetol) Patent Litigation with Hetero Labs Ltd. Axsome Therapeutics Enters $570 Million Term Loan and Revolving Credit Facility with Blackstone Axsome Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update Axsome Therapeutics and Mental Health America (MHA) Join Voices to Highlight Mental Health Month Axsome Therapeutics to Participate in Upcoming Investor Conferences Axsome Therapeutics to Report First Quarter 2025 Financial Results on May 5 Axsome Therapeutics Presents Positive Pivotal Phase 3 Results of the ACCORD-2 Trial of AXS-05 in Alzheimer’s Disease Agitation and the SYMPHONY Trial of AXS-12 in Narcolepsy at the 2025 American Academy of Neurology (AAN) Annual Meeting Axsome Therapeutics Announces Topline Results of PARADIGM Phase 3 Proof-of-Concept Trial of Solriamfetol in Major Depressive Disorder (MDD) with and without Excessive Daytime Sleepiness (EDS) Axsome Therapeutics Announces FOCUS Phase 3 Trial of Solriamfetol in Adults with Attention Deficit Hyperactivity Disorder (ADHD) Achieves Primary Endpoint Axsome Therapeutics Settles Sunosi® (solriamfetol) Patent Litigation with Hikma Pharmaceuticals USA Axsome Therapeutics Announces FDA Pre-NDA Meeting Minutes for AXS-05 in Alzheimer’s Disease Agitation Supporting NDA Submission Axsome Therapeutics to Participate in Upcoming Investor Conferences Axsome Therapeutics Announces SYMBRAVO® (meloxicam and rizatriptan) Achieves Primary Endpoint in the EMERGE Phase 3 Trial in Migraine Patients Experiencing Inadequate Response to Oral CGRP Inhibitors Axsome Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update Axsome Therapeutics Announces Settlement Agreement Resolving AUVELITY® (dextromethorphan HBr – bupropion HCl) Patent Litigation Axsome Therapeutics Hosts SYMBRAVO® FDA Approval Virtual Investor Event with Expert Thought Leader Axsome Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on February 18 Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2024 Net Revenue Axsome Therapeutics Announces Successful Completion and Results of Phase 3 Clinical Program of AXS-05 in Alzheimer’s Disease Agitation Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in ENCORE Long-Term Phase 3 Trial in Narcolepsy Axsome Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update Axsome Therapeutics Presents Data from Its Leading Neuroscience Pipeline at NEI Congress 2024 Axsome Therapeutics Presents Data from Multiple Programs Spanning Its Innovative Neuroscience Portfolio at Psych Congress 2024 Axsome Therapeutics to Report Third Quarter 2024 Financial Results on November 12 Axsome Therapeutics Presents Data from Multiple Programs at Sleep Europe 2024 Axsome Therapeutics Announces FDA Acceptance of NDA Resubmission for AXS-07 for the Acute Treatment of Migraine Axsome Therapeutics to Participate in Investor Conferences in September Axsome Therapeutics Reaches Agreement to Dismiss Sunosi® (Solriamfetol) Patent Litigation with Sandoz Inc. Axsome Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update Axsome Therapeutics to Report Second Quarter 2024 Financial Results on August 5 Axsome Therapeutics Settles Sunosi® (solriamfetol) Patent Litigation with Unichem Laboratories Axsome Therapeutics Joins the American Migraine Foundation to Highlight Unmet Treatment Needs During Migraine & Headache Awareness Month Axsome Therapeutics Supports Alzheimer’s & Brain Awareness Month Axsome Therapeutics to Participate in Upcoming Investor Conferences Axsome Therapeutics Highlights Data on Solriamfetol Demonstrating Improvement in Cognitive Function in Patients with Obstructive Sleep Apnea or Narcolepsy at SLEEP 2024 Axsome Therapeutics Presents Data from Multiple Programs at the 2024 American Society of Clinical Psychopharmacology Annual (ASCP) Meeting Axsome Therapeutics to Present at Upcoming Investor Conferences Axsome Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update Axsome Therapeutics Highlights Innovative Neuroscience Portfolio at the American Academy of Neurology (AAN) 2024 Annual Meeting Axsome Therapeutics to Report First Quarter 2024 Financial Results on May 6 Axsome Therapeutics Initiates ENGAGE Phase 3 Trial of Solriamfetol for the Treatment of Binge Eating Disorder Axsome Therapeutics Announces Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Needs in Treated Narcolepsy Type 1 Patients Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in the SYMPHONY Phase 3 Trial in Narcolepsy Axsome Therapeutics Initiates PARADIGM Phase 3 Trial of Solriamfetol for the Treatment of Major Depressive Disorder Axsome Therapeutics to Present at the Leerink Partners Global Biopharma Conference Axsome Therapeutics to Present at the TD Cowen 44th Annual Healthcare Conference Axsome Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update Axsome Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on February 20 Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2023 Net Revenue and 2024 Anticipated Milestones Axsome Therapeutics Presents New Data and Post-Hoc Analyses of Auvelity® in Patients with Major Depressive Disorder at the American College of Neuropsychopharmacology (ACNP) 2023 Annual Meeting Axsome Therapeutics Hosts Solriamfetol Virtual Investor Event with Expert Thought Leaders Today Axsome Therapeutics to Host Solriamfetol Virtual Investor Event on December 7 Axsome Therapeutics to Present at the Piper Sandler 35th Annual Healthcare Conference Axsome Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update Axsome Therapeutics and the Global Alzheimer’s Disease Community Come Together in Raising Support for the Millions Affected by This Illness During Alzheimer’s Disease Awareness Month 2023 Axsome Therapeutics to Present at Upcoming Investor Conferences Axsome Therapeutics Presents Results of the ACCORD trial of AXS-05 in Alzheimer’s Disease Agitation at the Clinical Trials on Alzheimer’s Disease (CTAD) 2023 Conference Axsome Therapeutics Appoints Dr. Sue Mahony to its Board of Directors Axsome Therapeutics to Report Third Quarter 2023 Financial Results on November 6 Axsome Therapeutics Joins the Global Narcolepsy Community in Raising Awareness on World Narcolepsy Day Axsome Therapeutics to Present at Three Upcoming Investor Conferences Axsome Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update Axsome Therapeutics to Report Second Quarter 2023 Financial Results on August 7 Axsome Therapeutics Initiates FOCUS Phase 3 Trial of Solriamfetol for the Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in Adults Axsome Therapeutics Announces Closing of Public Offering of $225 Million of Shares of Common Stock Axsome Therapeutics Announces Pricing of Public Offering of $225 Million of Shares of Common Stock Axsome Therapeutics Announces Proposed Public Offering of Common Stock Axsome Therapeutics to Present New Sunosi® Data at SLEEP 2023 Axsome Therapeutics to Present Data and Post-Hoc Analyses on Auvelity® and Sunosi® at the 2023 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting Axsome Therapeutics Reports First Quarter 2023 Financial Results and Corporate Update Axsome Therapeutics to Present at the Bank of America Securities 2023 Healthcare Conference Axsome Therapeutics to Present Five Abstracts Including New Data from the Positive SHARP Study of SUNOSI® (solriamfetol) in Participants with Cognitive Impairment with Excessive Daytime Sleepiness in Obstructive Sleep Apnea at the 2023 American Academy of Neurology (AAN) Annual Meeting Axsome Therapeutics to Present at the 22nd Annual Needham Virtual Healthcare Conference Axsome Therapeutics to Report First Quarter 2023 Financial Results on May 8 Axsome Therapeutics to Present at Cowen’s 43rd Annual Health Care Conference Axsome Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update Axsome Therapeutics Enters into License Agreement with Pharmanovia to Expand Commercialization and Further Develop Sunosi® (solriamfetol) in Europe Axsome Therapeutics to Present at the SVB Securities Global Biopharma Conference Axsome Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on February 27 Axsome Therapeutics Presents New Data from the EVOLVE Open-Label Trial Demonstrating Effects of AUVELITY® on Cognitive and Physical Functioning in Patients with Major Depressive Disorder at the American College of Neuropsychopharmacology (ACNP) 2022 Annual Meeting Axsome Therapeutics Announces AXS-05 Achieves Primary Endpoint in the ACCORD Phase 3 Trial in Alzheimer’s Disease Agitation Axsome Therapeutics to Present at the 5th Annual Evercore ISI HealthCONx Conference Axsome Therapeutics to Present at the Guggenheim 4th Annual Immunology and Neurology Conference Axsome Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update Axsome Therapeutics to Ring the NASDAQ Stock Market Opening Bell Today Axsome Therapeutics to Report Third Quarter 2022 Financial Results on November 7, 2022 Axsome Therapeutics Announces Availability of AUVELITY™, the First and Only Oral NMDA Receptor Antagonist for the Treatment of Major Depressive Disorder in Adults Axsome Therapeutics Announces Sunosi® (Solriamfetol) Meets Primary Endpoint Demonstrating Improvement in Cognitive Function in the SHARP Trial in Cognitively Impaired Patients with Excessive Daytime Sleepiness Associated with Obstructive Sleep Apnea Axsome Therapeutics Announces Plans to Resubmit AXS-07 NDA Based on Successful FDA Type A Meeting Axsome Therapeutics to Present at the Ladenburg Thalmann Healthcare Conference Axsome Therapeutics to Present at the Cowen 2nd Annual Novel Mechanisms in Neuropsychiatry Summit Axsome Therapeutics Initiates ADVANCE-2 Phase 3 Trial of AXS-05 in Alzheimer’s Disease Agitation Axsome Therapeutics Announces Publication of Post-hoc Analysis of Sunosi® Effect on Excessive Daytime Sleepiness in Narcolepsy or Obstructive Sleep Apnea Patients with a History of Depression in the Journal of Psychiatric Research Axsome Therapeutics to Present at the Morgan Stanley 20th Annual Global Healthcare Conference Axsome Therapeutics Initiates EMERGE Phase 3 Open-Label Trial of AXS-07 for the Acute Treatment of Migraine in Adults with a Prior Inadequate Response to an Oral CGRP Inhibitor Axsome Therapeutics Announces FDA Approval of AUVELITY™, the First and Only Oral NMDA Receptor Antagonist for the Treatment of Major Depressive Disorder in Adults Axsome Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update Axsome Therapeutics to Report Second Quarter 2022 Financial Results on August 9, 2022 Axsome Therapeutics Hosts Sunosi® Investor Update Virtual Event Today with Key Opinion Leaders Axsome Therapeutics to Host Sunosi® Investor Update Virtual Event Axsome Therapeutics Announces Results of the SUPPORT Survey of Patients with Major Depressive Disorder Presented at the American Society of Clinical Psychopharmacology Association (ASCP) 2022 Annual Meeting Axsome Therapeutics Presents New Data from the GEMINI Trial Demonstrating Efficacy of AXS-05 on Anhedonia in Patients with Major Depressive Disorder Axsome Therapeutics Announces Late-Breaking Presentations of Positive Results of the EVOLVE Trial of AXS-05 in Major Depressive Disorder After Prior Treatment Failures at the American Society of Clinical Psychopharmacology (ASCP) 2022 Annual Meeting Axsome Therapeutics Announces Publication of Pivotal GEMINI Phase 3 Trial of AXS-05 in Major Depressive Disorder in The Journal of Clinical Psychiatry Axsome Therapeutics Announces Publication of Pivotal ASCEND Phase 2 Trial of AXS-05 in Major Depressive Disorder in The American Journal of Psychiatry Axsome Therapeutics Completes U.S. Acquisition of Sunosi® (solriamfetol) for Excessive Daytime Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea Axsome Therapeutics Completes U.S. Acquisition of Sunosi® (solriamfetol) for Excessive Daytime Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea Jazz Pharmaceuticals Completes U.S. Divestiture of Sunosi® (solriamfetol) to Axsome Therapeutics Axsome Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update Axsome Therapeutics Receives FDA Complete Response Letter for New Drug Application for AXS-07 for the Acute Treatment of Migraine Axsome Therapeutics to Report First Quarter 2022 Financial Results on May 2, 2022 Axsome Therapeutics to Acquire Sunosi® from Jazz Pharmaceuticals, Expanding Axsome’s Leadership in Neuroscience Axsome Therapeutics to Participate in the 1st Annual Needham Virtual Neuroscience Forum Axsome Therapeutics to Present at the Cowen 42nd Annual Health Care Conference Axsome Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update Axsome Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results on March 1, 2022 Axsome Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference Axsome Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update Axsome Therapeutics to Report Third Quarter 2021 Financial Results on November 8, 2021 Axsome Therapeutics Expands Term Loan Facility with Hercules Capital to $300 Million Axsome Therapeutics Initiates SYMPHONY Phase 3 Trial of AXS-12 in Narcolepsy Axsome Therapeutics Announces FDA Acceptance of New Drug Application for AXS-07 for the Acute Treatment of Migraine Axsome Therapeutics Provides Update on the New Drug Application for AXS-05 for the Treatment of Major Depressive Disorder Axsome Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update Axsome Therapeutics Announces AXS-05 Achieves Primary and Key Secondary Endpoints in the MERIT Phase 2 Trial in Treatment Resistant Depression Axsome Therapeutics to Report Second Quarter 2021 Financial Results on August 9, 2021 Axsome Therapeutics Announces Planned NDA Submission for AXS-14 for the Management of Fibromyalgia Axsome Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update Axsome Therapeutics to Report First Quarter 2021 Financial Results on May 10, 2021 Axsome Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for AXS-05 for Treatment of Major Depressive Disorder Axsome Therapeutics Announces $225 Million Term Loan Facility with Hercules Capital Axsome Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update Axsome Therapeutics to Present at Upcoming Investor Conferences Axsome Therapeutics to Report Fourth Quarter and Full Year 2020 Financial Results on March 1, 2021 Axsome Therapeutics Initiates ACCORD Phase 3 Trial of AXS-05 in Alzheimer’s Disease Agitation Axsome Therapeutics Announces Positive Efficacy and Safety Results from the Phase 3 MOVEMENT Long-Term Trial of AXS-07 in the Acute Treatment of Migraine Axsome Therapeutics Announces Positive Results from the COMET-SI Trial of AXS-05 in Patients with Major Depressive Disorder Who Have Suicidal Ideation Axsome Therapeutics Announces Positive Results from the COMET-TRD Trial of AXS-05 in Patients with Treatment Resistant Depression Axsome Therapeutics Announces Positive Efficacy and Safety Results from Phase 3 COMET Long-Term Trial and COMET-AU Trial of AXS-05 in Major Depressive Disorder Axsome Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update Axsome Therapeutics and Veeva Systems Partner to Build Axsome’s Digital-Centric Commercialization™ Platform Axsome Therapeutics to Present Data from the ADVANCE-1 Trial of AXS-05 in Alzheimer’s Disease Agitation at the 13th Clinical Trials on Alzheimer’s Disease (CTAD) Conference Axsome Therapeutics to Report Third Quarter 2020 Financial Results on November 5, 2020 Axsome Therapeutics Announces $225 Million Term Loan Facility with Hercules Capital Axsome Therapeutics to Present at the Morgan Stanley 18th Annual Global Healthcare Conference Axsome Therapeutics Presents New Data from MOMENTUM Phase 3 Trial with AXS-07 Demonstrating Rapid Onset of Action and Reduced Symptom Recurrence in the Acute Treatment of Migraine Axsome Therapeutics Announces Expedited Development of AXS-12 for the Treatment of Narcolepsy Based on FDA Breakthrough Therapy Meeting Axsome Therapeutics Announces AXS-07 Phase 3 Migraine Trial Results Selected by the American Academy of Neurology Science Committee as Featured Presentation Axsome Therapeutics Presents New Data from GEMINI Phase 3 Trial with AXS-05 Demonstrating Rapid and Significant Improvements in Patient-Reported Outcomes in Major Depressive Disorder Axsome Therapeutics to Present New Data for AXS-05 in Major Depressive Disorder at the 33rd European College of Neuropsychopharmacology Congress Axsome Therapeutics to Present at Upcoming Investor Conferences Axsome Therapeutics Confirms Pivotal Status and Advancement of AXS-05 for the Treatment of Alzheimer’s Disease Agitation Based on Successful FDA Breakthrough Therapy Meeting Axsome Therapeutics to Present Data from the CONCERT Phase 2 Trial of AXS-12 in Narcolepsy at the SLEEP 2020 Annual Meeting Axsome Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business Update Axsome Therapeutics to Report Second Quarter 2020 Financial Results on August 10, 2020 Axsome Therapeutics to Present at Upcoming Investor Conferences Axsome Therapeutics Announces AXS-05 Achieves Primary Endpoint in the ADVANCE-1 Pivotal Phase 2/3 Trial in Alzheimer’s Disease Agitation Axsome Therapeutics Completes Successful FDA Pre-NDA Meeting for AXS-05 for the Treatment of Major Depressive Disorder Axsome Therapeutics to Report First Quarter 2020 Financial Results on May 8, 2020